Bayer logo
US MEDICAL AFFAIRS
Contact Us icon

Publications

Publications

Home / Publications 

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated March 2025.

IPPI: Immediate Postpartum Insertion

SD: Sleep Disturbances

PK: Pharmacokinetics

IUD: Intrauterine Device

VMS: Vasomotor Symptoms

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 38    

Filtered results: 38

Use of oral medications prior to IUD insertion - Trends and associations of patient characteristics in a large observational study in Europe (EURAS-LCS12)

Klinghardt M, et al. Eur J Obstet Gynecol Reprod Biol. 2025. Online ahead of print

Klinghardt M., Rizzo M., Boehnke T., Barnett C., Heinemann K., a,
READ
EMAIL

Trends in Endometriosis Management: A 10-Year US Claims Analysis

Lewis H, et al. J Minim Invasive Gynecol. 2025. Online ahead of print

Lewis H., Parisa-Fatemeh Asad Zadeh V.K., Soskin L., Worful J., ,
READ
EMAIL

Impact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review

Soares C, et al. Menopause. 2025. Online ahead of print

Soares C.N., Bajbouj M., Schoof N., Kishore A., and Caetano C. ,
READ
EMAIL

Elinzanetant for the treatment of vasomotor symptoms associated with menopause: A phase 3 randomized clinical trial

Panay N, et al. JAMA Intern Med. 2025. Online ahead of print.

Panay N., Joffe H., Maki P., Nappi R., Pinkerton J., Simon J., S,
READ
EMAIL

Real-world validation of a bleeding prediction algorithm in levonorgestrel intrauterine device users using the MyIUS mobile app

Vieira CS, et al. Contraception. 2025; 152:111201

Vieira C.S., Eggebrecht L., Milhoranca I.A., Neumann R., Acar M.,
READ
EMAIL

Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany

Saadedine M, et al. Menopause. 2025. Online ahead of print.

Saadedine M, Banks V, Dinkel-Keuthage C, Janssenswillen C, Laval,
READ
EMAIL

Characterization and Treatment Patterns of Peri/Menopausal and Postmenopausal Women with and Without Vasomotor Symptoms in a Retrospective Database Study

Charafi L, Womens Health Rep (New Rochelle). 2025; 6(1):742-751.

Charafi L., Bolling K., Schroader BK., and Halvorson L.,
READ
EMAIL

Treatments in women experiencing natural menopause: a cohort study from the USA, the UK and Germany

Saadedine M, et al. Climacteric. 2025. Online ahead of print.

Saadedine M., Banks V., Dinkel-Keuthage C., Caetano C., Argyriou,
READ
EMAIL

Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes

Haberland C., et al. J Patient Rep Outcomes. 2025; 9(1):79

Haberland C., Barclay M., Whyman S., Lehane A., Gater A., Gerlin,
READ
EMAIL

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Cardoso F, et al. N Engl J Med. 2025. Online ahead of print.

Cardoso F., Parke S., Brennan D.J., Briggs P., Donders G., Panay,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 09/2025